NASDAQ:BBIO | Free Cash Flow | BridgeBio Pharma, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2017-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$197.28M$69,000.00-$197.35M
2025-12-31-$56.42M$33,000.00-$56.45M
2025-03-31-$199.24M$0.00-$199.24M
2024-12-31-$195.33M$47,000.00-$195.37M
2024-03-31-$219.54M$695,000.00-$220.23M
2023-12-31-$124.82M$435,000.00-$125.25M
2023-03-31-$144.32M$12,000.00-$144.33M
2022-12-31-$93.24M$801,000.00-$94.04M
2022-03-31-$160.64M$859,000.00-$161.49M
2021-12-31-$133.9M$2.54M-$136.43M
2021-03-31-$150.77M$1.96M-$152.73M
2020-12-31-$96.26M$2.15M-$98.41M
2020-03-31-$83.92M$4.48M-$88.4M
2019-12-31-$76.2M$1.75M-$77.95M
2019-03-31-$59.14M$427,000.00-$59.57M
2018-12-31-$46.41M$741,000.00-$47.16M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$445.91M$1.1M-$447.01M
2024-12-31-$520.73M$933,000.00-$521.66M
2023-12-31-$527.72M$1.31M-$529.03M
2022-12-31-$419.49M$4.82M-$424.32M
2021-12-31-$497.93M$13.25M-$511.18M
2020-12-31-$399.71M$7.52M-$407.23M
2019-12-31-$253.59M$2.64M-$256.23M
2018-12-31-$136.64M$2.18M-$138.82M
2017-12-31-$40.49M$464,000.00-$40.95M